TITLE

Clofibrate

PUB. DATE
September 1970
SOURCE
British Medical Journal;9/12/1970, Vol. 3 Issue 5723, p632
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
64097974

 

Related Articles

  • Clofibrate and the primary prevention of ischaemic heart disease.  // British Medical Journal;12/9/1978, Vol. 2 Issue 6152, p1585 

    Focuses on the clofibrate and the primary prevention of Ischemic heart diseases. Value of clofibrate; Possibilities on the blasting outward; Conclusions on the report.

  • Clofibrate in Ischemic Heart Disease.  // Annals of Internal Medicine;May72, Vol. 76 Issue 5, p821 

    Comments on an article about the prevention trials of clofibrate in ischemic heart disease. Description of the condition of patients; Details on the lipid-lowering properties of clofibrate.

  • Acute renal failure and interstitial nephritis after clofibrate treatment. Cumming, Allan // British Medical Journal;12/6/1980, Vol. 281 Issue 6254, p1529 

    Reports the acute reversible renal failure due to interstitial nephritis. Treatment of renal failure with clofibrate; Association of clofibrate with several adverse reactions Reference on an insulin dependent diabetic patient.

  • Electropolymerized Molecularly Imprinted Polypyrrole Film for Sensing of Clofibric Acid. Schweiger, Bianca; Jungtae Kim; Young Jun Kim; Ulbricht, Mathias // Sensors (14248220);2015, Vol. 15 Issue 3, p4870 

    Piezoelectric quartz crystals and analogous gold substrates were electrochemically coated with molecularly imprinted polypyrrole films for pulsed amperometric detection (PAD) of clofibric acid, a metabolite of clofibrate. Cyclic voltammetry data obtained during polymerization and deposited...

  • Intrahepatic Cholestasis Following the Use of Atromid-S. Valdes, Mariano; Jacobs, Walter H. // American Journal of Gastroenterology;Jul1976, Vol. 66 Issue 1, p69 

    Presents a case report on the use of Atromid-S, a clofibrate, to treat a patient with hyperlipidemia. Side effects of clofibrate; Decline in alkaline phosphatase levels in the patient after the medication was discontinued; Observation on aspartate aminotransferase and mucoprotein levels in the...

  • AN EFFECTIVE TREATMENT OF HYPERCHOLESTEROLAEMIA USING A COMBINATION OF SECHOLEX® AND CLOFIBRATE. Evans, R. J. Courtenay; Howard, A. N.; Hyams, D. E. // Angiology;Jan1973, Vol. 24 Issue 1, p22 

    Secholex® (PDX chloride) is a palatable anion exchange resin which is effective alone but better tolerated than Questran®. When the anion exchange resins were combined with clofibrate, synergism occurred. Simultaneous dosage of Secholex® (15 g/day) and clofibrate (1.5 g/day) was...

  • Reversal of clofibrate-induced cholesterol oversaturation of bile with chenodeoxycholic acid. Bateson, M.C.; Ross, P.E.; Murison, J.; Bouchier, Ian A.D. // British Medical Journal;5/6/1978, Vol. 1 Issue 6121, p1171 

    Giving clofibrate 2 g daily to seven patients significantly increased the biliary cholesterol concentration while the proportion of bile acids fell. Five patients on established clofibrate treatment were given 750 mg of chenodeoxycholic acid (CDCA) daily for one month. Biliary lipid analysis...

  • Effect of clofibrate on serum triglyceride and cholesterol after intravenous lipid in very low birth weight neonates. Mohammadzadeh, A.; Farhat, A. S.; Esmaeli, H.; Amiri, R. // Iranian Journal of Neonatology;Autumn2013, Vol. 4 Issue 3, p20 

    Background Lipoprotein lipase activity can be increased by clofibrate. Clofibrate is used to reduce serum triglyceride level in adults. The aim of this study was to determine the effect of clofibrate on serum triglyceride and cholesterol level after administration of intravenous lipid in very...

  • Clofibrate Prevents and Reverses the Hemodynamic Manifestations of Hyperthyroidism in Rats. Rodríguez-Gómez, Isabel; Cruz, Antonio; Moreno, Juan Manuel; Soler, Agatángelo; Osuna, Antonio; Vargas, Félix // American Journal of Hypertension;Mar2008, Vol. 21 Issue 3, p341 

    BACKGROUND This study analyzed the effects of the chronic administration of clofibrate, a peroxisome proliferator-activated receptor-α (PPARα) agonist, on the development and established hemodynamic, morphologic, metabolic, and renal manifestations of hyperthyroidism in rats. METHODS The...

  • A Comparative Study on the Effectiveness of Garlic with Clofibrate in the Treatment of Hyperlipidemia. Nouri, M.; Pipelzadeh, M. H.; Badiei, A. // Journal of Medical Sciences;2008, Vol. 8 Issue 1, p85 

    In this study, the effectiveness of standardised garlic tablets (Kwai) was compared with clofibrate in the treatment of hyperlipidaemia. A total of 20 patients with total cholesterol and triglyceride values above 200 and 280 mg dL-1, respectively, voluntarily took part in tiffs study. Patients...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics